Apyx Medical Corp Dossier
Qualitative Analysis
Business overview
Apyx Medical Corporation (formerly Bovie Medical Corporation) is an energy-based medical technology company specializing in the surgical aesthetics and medical device markets. The company is best known for its proprietary Helium Plasma Platform Technology, which is marketed and sold under the Renuvion brand in the cosmetic surgery market and J-Plasma in the hospital surgical market. These systems deliver controlled radiofrequency (RF) energy and helium plasma to cut, coagulate, and ablate soft tissue, causing subdermal collagen fibers to heat rapidly and contract, resulting in skin retraction. Additionally, Apyx Medical operates an Original Equipment Manufacturing (OEM) segment, leveraging its expertise in unique waveforms to design and manufacture electrosurgical generators and related accessories for other medical device manufacturers.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Scaling the U.S. commercial launch of the AYON Body Contouring System, an all-in-one platform integrating fat removal, closed-loop contouring, electrosurgical capabilities, and Renuvion tissue contraction.
Expected impact: Drives significant growth in the Surgical Aesthetics segment and increases high-margin single-use handpiece sales.
Implementing a cost-saving restructuring program, including a 25% reduction in the U.S. workforce, board size reduction from eight to five members, and identifying over $4 million in additional cost savings.
Expected impact: Reduces annual operating expenses to less than $45 million in 2026, narrowing net losses and extending cash runway through 2027.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Serves as the exclusive commercial foundation for marketing and selling Renuvion helium plasma technology in China, one of the world's largest and fastest-growing medical aesthetics markets.
Terms: Operations commenced in Q2 2025 through a China Joint Venture variable interest entity (VIE) structure.